Now known as Standard BioTools Inc, Fluidigm’s technologies and products based on microfluidics and mass cytometry enable the exploration and analysis of individual cells, as well as the industrial application of genomics. Listed on NASDAQ in 2011.
A large-scale cell culture manufacturing site for the production of monoclonal antibodies and recombinant proteins. Acquired by Lonza Group in 2008.
Pioneers the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body’s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. Listed on NASDAQ in 2018.
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates to improve the quality of life and survival for people with cancer.
I-Mab is a full-stack biopharmaceutical company equipped to discover and develop best- and first-in-class biologics with global potential to treat cancer and auto-immune diseases.
I-MAB Biopharmaceutical Read More »
Deciphering complex biology with NetMAPPR platform, integrating data science, machine learning, high-throughput experiments, combinatorial genetics, and drug discovery, to yield promising drug targets for precision oncology therapeutics.
Engine Biosciences Read More »
US2.AI (formerly eko.ai) is automating the fight against heart disease, using AI software to simplify and democratize ultrasound of the heart, the most commonly used tool for the detection of cardiovascular risk.
Aetion is a health care technology company that delivers real-world evidence for biopharma companies, payers, regulators, and HTA agencies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value across the product life cycle.
Nuevocor is an IND-stage biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in Singapore with an office in the U.S. and expanding to Europe.
Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.
